nodes	percent_of_prediction	percent_of_DWPC	metapath
Levomilnacipran—ABCB1—ovarian cancer	0.404	1	CbGaD
Levomilnacipran—ABCB1—Topotecan—ovarian cancer	0.0626	0.162	CbGbCtD
Levomilnacipran—CYP2C8—Paclitaxel—ovarian cancer	0.0457	0.119	CbGbCtD
Levomilnacipran—ABCB1—Vinorelbine—ovarian cancer	0.0441	0.114	CbGbCtD
Levomilnacipran—CYP2D6—Vinorelbine—ovarian cancer	0.0415	0.108	CbGbCtD
Levomilnacipran—CYP3A4—Topotecan—ovarian cancer	0.0375	0.0972	CbGbCtD
Levomilnacipran—ABCB1—Paclitaxel—ovarian cancer	0.031	0.0803	CbGbCtD
Levomilnacipran—CYP3A4—Vinorelbine—ovarian cancer	0.0264	0.0685	CbGbCtD
Levomilnacipran—ABCB1—Docetaxel—ovarian cancer	0.0224	0.0581	CbGbCtD
Levomilnacipran—CYP3A4—Paclitaxel—ovarian cancer	0.0186	0.0481	CbGbCtD
Levomilnacipran—ABCB1—Doxorubicin—ovarian cancer	0.0167	0.0433	CbGbCtD
Levomilnacipran—CYP2D6—Doxorubicin—ovarian cancer	0.0157	0.0408	CbGbCtD
Levomilnacipran—CYP3A4—Docetaxel—ovarian cancer	0.0134	0.0348	CbGbCtD
Levomilnacipran—CYP3A4—Doxorubicin—ovarian cancer	0.01	0.0259	CbGbCtD
Levomilnacipran—CYP2J2—endometrium—ovarian cancer	0.000733	0.088	CbGeAlD
Levomilnacipran—CYP2J2—uterus—ovarian cancer	0.000675	0.0811	CbGeAlD
Levomilnacipran—CYP2J2—female reproductive system—ovarian cancer	0.000607	0.0729	CbGeAlD
Levomilnacipran—CYP2J2—vagina—ovarian cancer	0.000549	0.0659	CbGeAlD
Levomilnacipran—CYP2J2—testis—ovarian cancer	0.00049	0.0588	CbGeAlD
Levomilnacipran—SLC6A2—decidua—ovarian cancer	0.000366	0.044	CbGeAlD
Levomilnacipran—SLC6A4—female reproductive system—ovarian cancer	0.000327	0.0393	CbGeAlD
Levomilnacipran—SLC6A2—gonad—ovarian cancer	0.000323	0.0387	CbGeAlD
Levomilnacipran—Hyponatraemia—Doxorubicin—ovarian cancer	0.000311	0.00165	CcSEcCtD
Levomilnacipran—Loss of consciousness—Paclitaxel—ovarian cancer	0.00031	0.00164	CcSEcCtD
Levomilnacipran—Mediastinal disorder—Docetaxel—ovarian cancer	0.00031	0.00164	CcSEcCtD
Levomilnacipran—Liver function test abnormal—Epirubicin—ovarian cancer	0.000309	0.00164	CcSEcCtD
Levomilnacipran—Rash—Melphalan—ovarian cancer	0.000309	0.00164	CcSEcCtD
Levomilnacipran—Dermatitis—Melphalan—ovarian cancer	0.000309	0.00163	CcSEcCtD
Levomilnacipran—Chills—Docetaxel—ovarian cancer	0.000308	0.00163	CcSEcCtD
Levomilnacipran—Asthenia—Vinorelbine—ovarian cancer	0.000307	0.00163	CcSEcCtD
Levomilnacipran—Dry skin—Epirubicin—ovarian cancer	0.000307	0.00163	CcSEcCtD
Levomilnacipran—Convulsion—Paclitaxel—ovarian cancer	0.000306	0.00162	CcSEcCtD
Levomilnacipran—Migraine—Doxorubicin—ovarian cancer	0.000305	0.00162	CcSEcCtD
Levomilnacipran—Hypertension—Paclitaxel—ovarian cancer	0.000305	0.00161	CcSEcCtD
Levomilnacipran—Pruritus—Vinorelbine—ovarian cancer	0.000303	0.0016	CcSEcCtD
Levomilnacipran—Breast disorder—Epirubicin—ovarian cancer	0.000303	0.0016	CcSEcCtD
Levomilnacipran—Mental disorder—Docetaxel—ovarian cancer	0.000301	0.00159	CcSEcCtD
Levomilnacipran—Chest pain—Paclitaxel—ovarian cancer	0.0003	0.00159	CcSEcCtD
Levomilnacipran—Anxiety—Paclitaxel—ovarian cancer	0.000299	0.00158	CcSEcCtD
Levomilnacipran—Malnutrition—Docetaxel—ovarian cancer	0.000299	0.00158	CcSEcCtD
Levomilnacipran—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—ovarian cancer	0.000298	0.00158	CcSEcCtD
Levomilnacipran—Nausea—Topotecan—ovarian cancer	0.000297	0.00157	CcSEcCtD
Levomilnacipran—Dry mouth—Paclitaxel—ovarian cancer	0.000294	0.00156	CcSEcCtD
Levomilnacipran—Diarrhoea—Vinorelbine—ovarian cancer	0.000293	0.00155	CcSEcCtD
Levomilnacipran—Dysgeusia—Docetaxel—ovarian cancer	0.000293	0.00155	CcSEcCtD
Levomilnacipran—Abdominal distension—Epirubicin—ovarian cancer	0.000291	0.00154	CcSEcCtD
Levomilnacipran—Nausea—Melphalan—ovarian cancer	0.000291	0.00154	CcSEcCtD
Levomilnacipran—SLC6A2—female reproductive system—ovarian cancer	0.000288	0.0346	CbGeAlD
Levomilnacipran—Liver function test abnormal—Doxorubicin—ovarian cancer	0.000286	0.00151	CcSEcCtD
Levomilnacipran—Infection—Paclitaxel—ovarian cancer	0.000286	0.00151	CcSEcCtD
Levomilnacipran—CYP2C8—endometrium—ovarian cancer	0.000286	0.0343	CbGeAlD
Levomilnacipran—Dry skin—Doxorubicin—ovarian cancer	0.000284	0.0015	CcSEcCtD
Levomilnacipran—Shock—Paclitaxel—ovarian cancer	0.000283	0.0015	CcSEcCtD
Levomilnacipran—Dizziness—Vinorelbine—ovarian cancer	0.000283	0.0015	CcSEcCtD
Levomilnacipran—Nervous system disorder—Paclitaxel—ovarian cancer	0.000282	0.0015	CcSEcCtD
Levomilnacipran—Angina pectoris—Epirubicin—ovarian cancer	0.000282	0.00149	CcSEcCtD
Levomilnacipran—Thrombocytopenia—Paclitaxel—ovarian cancer	0.000282	0.00149	CcSEcCtD
Levomilnacipran—Tachycardia—Paclitaxel—ovarian cancer	0.000281	0.00149	CcSEcCtD
Levomilnacipran—Breast disorder—Doxorubicin—ovarian cancer	0.00028	0.00148	CcSEcCtD
Levomilnacipran—Skin disorder—Paclitaxel—ovarian cancer	0.00028	0.00148	CcSEcCtD
Levomilnacipran—Hyperhidrosis—Paclitaxel—ovarian cancer	0.000278	0.00147	CcSEcCtD
Levomilnacipran—Anorexia—Paclitaxel—ovarian cancer	0.000274	0.00145	CcSEcCtD
Levomilnacipran—Vomiting—Vinorelbine—ovarian cancer	0.000272	0.00144	CcSEcCtD
Levomilnacipran—Neutropenia—Epirubicin—ovarian cancer	0.000271	0.00143	CcSEcCtD
Levomilnacipran—Dysuria—Epirubicin—ovarian cancer	0.000271	0.00143	CcSEcCtD
Levomilnacipran—Rash—Vinorelbine—ovarian cancer	0.00027	0.00143	CcSEcCtD
Levomilnacipran—Dermatitis—Vinorelbine—ovarian cancer	0.00027	0.00143	CcSEcCtD
Levomilnacipran—Abdominal distension—Doxorubicin—ovarian cancer	0.00027	0.00143	CcSEcCtD
Levomilnacipran—Hypotension—Paclitaxel—ovarian cancer	0.000269	0.00142	CcSEcCtD
Levomilnacipran—Upper respiratory tract infection—Epirubicin—ovarian cancer	0.000269	0.00142	CcSEcCtD
Levomilnacipran—Headache—Vinorelbine—ovarian cancer	0.000268	0.00142	CcSEcCtD
Levomilnacipran—Syncope—Docetaxel—ovarian cancer	0.000268	0.00142	CcSEcCtD
Levomilnacipran—Leukopenia—Docetaxel—ovarian cancer	0.000268	0.00142	CcSEcCtD
Levomilnacipran—Pollakiuria—Epirubicin—ovarian cancer	0.000267	0.00142	CcSEcCtD
Levomilnacipran—Palpitations—Docetaxel—ovarian cancer	0.000264	0.0014	CcSEcCtD
Levomilnacipran—Loss of consciousness—Docetaxel—ovarian cancer	0.000263	0.00139	CcSEcCtD
Levomilnacipran—Weight decreased—Epirubicin—ovarian cancer	0.000262	0.00139	CcSEcCtD
Levomilnacipran—Angina pectoris—Doxorubicin—ovarian cancer	0.000261	0.00138	CcSEcCtD
Levomilnacipran—Insomnia—Paclitaxel—ovarian cancer	0.00026	0.00138	CcSEcCtD
Levomilnacipran—Convulsion—Docetaxel—ovarian cancer	0.000259	0.00137	CcSEcCtD
Levomilnacipran—Paraesthesia—Paclitaxel—ovarian cancer	0.000259	0.00137	CcSEcCtD
Levomilnacipran—Hypertension—Docetaxel—ovarian cancer	0.000258	0.00137	CcSEcCtD
Levomilnacipran—Dyspnoea—Paclitaxel—ovarian cancer	0.000257	0.00136	CcSEcCtD
Levomilnacipran—Somnolence—Paclitaxel—ovarian cancer	0.000256	0.00136	CcSEcCtD
Levomilnacipran—Stevens-Johnson syndrome—Epirubicin—ovarian cancer	0.000256	0.00135	CcSEcCtD
Levomilnacipran—Chest pain—Docetaxel—ovarian cancer	0.000255	0.00135	CcSEcCtD
Levomilnacipran—Nausea—Vinorelbine—ovarian cancer	0.000254	0.00135	CcSEcCtD
Levomilnacipran—Dyspepsia—Paclitaxel—ovarian cancer	0.000253	0.00134	CcSEcCtD
Levomilnacipran—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.000253	0.00134	CcSEcCtD
Levomilnacipran—Urinary tract infection—Epirubicin—ovarian cancer	0.000251	0.00133	CcSEcCtD
Levomilnacipran—Dysuria—Doxorubicin—ovarian cancer	0.00025	0.00133	CcSEcCtD
Levomilnacipran—Neutropenia—Doxorubicin—ovarian cancer	0.00025	0.00133	CcSEcCtD
Levomilnacipran—Decreased appetite—Paclitaxel—ovarian cancer	0.00025	0.00133	CcSEcCtD
Levomilnacipran—Dry mouth—Docetaxel—ovarian cancer	0.000249	0.00132	CcSEcCtD
Levomilnacipran—Upper respiratory tract infection—Doxorubicin—ovarian cancer	0.000249	0.00132	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.000249	0.00132	CcSEcCtD
Levomilnacipran—Fatigue—Paclitaxel—ovarian cancer	0.000248	0.00131	CcSEcCtD
Levomilnacipran—Pollakiuria—Doxorubicin—ovarian cancer	0.000247	0.00131	CcSEcCtD
Levomilnacipran—Constipation—Paclitaxel—ovarian cancer	0.000246	0.0013	CcSEcCtD
Levomilnacipran—Haematuria—Epirubicin—ovarian cancer	0.000246	0.0013	CcSEcCtD
Levomilnacipran—CYP2C19—vagina—ovarian cancer	0.000245	0.0295	CbGeAlD
Levomilnacipran—Hepatobiliary disease—Epirubicin—ovarian cancer	0.000244	0.00129	CcSEcCtD
Levomilnacipran—Infection—Docetaxel—ovarian cancer	0.000242	0.00128	CcSEcCtD
Levomilnacipran—Weight decreased—Doxorubicin—ovarian cancer	0.000242	0.00128	CcSEcCtD
Levomilnacipran—Shock—Docetaxel—ovarian cancer	0.00024	0.00127	CcSEcCtD
Levomilnacipran—Nervous system disorder—Docetaxel—ovarian cancer	0.000239	0.00127	CcSEcCtD
Levomilnacipran—Thrombocytopenia—Docetaxel—ovarian cancer	0.000239	0.00127	CcSEcCtD
Levomilnacipran—Tachycardia—Docetaxel—ovarian cancer	0.000238	0.00126	CcSEcCtD
Levomilnacipran—Skin disorder—Docetaxel—ovarian cancer	0.000237	0.00126	CcSEcCtD
Levomilnacipran—Stevens-Johnson syndrome—Doxorubicin—ovarian cancer	0.000237	0.00125	CcSEcCtD
Levomilnacipran—CYP2C8—female reproductive system—ovarian cancer	0.000237	0.0284	CbGeAlD
Levomilnacipran—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.000235	0.00125	CcSEcCtD
Levomilnacipran—CYP2J2—Phase 1 - Functionalization of compounds—CYP1B1—ovarian cancer	0.000235	0.0174	CbGpPWpGaD
Levomilnacipran—Anorexia—Docetaxel—ovarian cancer	0.000233	0.00123	CcSEcCtD
Levomilnacipran—SLC6A2—testis—ovarian cancer	0.000233	0.0279	CbGeAlD
Levomilnacipran—Urinary tract infection—Doxorubicin—ovarian cancer	0.000232	0.00123	CcSEcCtD
Levomilnacipran—Hepatitis—Epirubicin—ovarian cancer	0.000232	0.00123	CcSEcCtD
Levomilnacipran—Hypoaesthesia—Epirubicin—ovarian cancer	0.000231	0.00122	CcSEcCtD
Levomilnacipran—Urinary tract disorder—Epirubicin—ovarian cancer	0.000229	0.00121	CcSEcCtD
Levomilnacipran—Urticaria—Paclitaxel—ovarian cancer	0.000229	0.00121	CcSEcCtD
Levomilnacipran—Oedema peripheral—Epirubicin—ovarian cancer	0.000228	0.00121	CcSEcCtD
Levomilnacipran—Hypotension—Docetaxel—ovarian cancer	0.000228	0.00121	CcSEcCtD
Levomilnacipran—Haematuria—Doxorubicin—ovarian cancer	0.000228	0.00121	CcSEcCtD
Levomilnacipran—Connective tissue disorder—Epirubicin—ovarian cancer	0.000228	0.00121	CcSEcCtD
Levomilnacipran—Body temperature increased—Paclitaxel—ovarian cancer	0.000228	0.00121	CcSEcCtD
Levomilnacipran—Abdominal pain—Paclitaxel—ovarian cancer	0.000228	0.00121	CcSEcCtD
Levomilnacipran—Urethral disorder—Epirubicin—ovarian cancer	0.000227	0.0012	CcSEcCtD
Levomilnacipran—Hepatobiliary disease—Doxorubicin—ovarian cancer	0.000226	0.0012	CcSEcCtD
Levomilnacipran—Insomnia—Docetaxel—ovarian cancer	0.000221	0.00117	CcSEcCtD
Levomilnacipran—Paraesthesia—Docetaxel—ovarian cancer	0.000219	0.00116	CcSEcCtD
Levomilnacipran—Erythema multiforme—Epirubicin—ovarian cancer	0.000219	0.00116	CcSEcCtD
Levomilnacipran—Dyspnoea—Docetaxel—ovarian cancer	0.000218	0.00115	CcSEcCtD
Levomilnacipran—Somnolence—Docetaxel—ovarian cancer	0.000217	0.00115	CcSEcCtD
Levomilnacipran—Eye disorder—Epirubicin—ovarian cancer	0.000217	0.00115	CcSEcCtD
Levomilnacipran—Cardiac disorder—Epirubicin—ovarian cancer	0.000215	0.00114	CcSEcCtD
Levomilnacipran—Flushing—Epirubicin—ovarian cancer	0.000215	0.00114	CcSEcCtD
Levomilnacipran—Dyspepsia—Docetaxel—ovarian cancer	0.000215	0.00114	CcSEcCtD
Levomilnacipran—Hepatitis—Doxorubicin—ovarian cancer	0.000214	0.00114	CcSEcCtD
Levomilnacipran—CYP2C8—vagina—ovarian cancer	0.000214	0.0257	CbGeAlD
Levomilnacipran—Hypoaesthesia—Doxorubicin—ovarian cancer	0.000213	0.00113	CcSEcCtD
Levomilnacipran—Decreased appetite—Docetaxel—ovarian cancer	0.000212	0.00112	CcSEcCtD
Levomilnacipran—Hypersensitivity—Paclitaxel—ovarian cancer	0.000212	0.00112	CcSEcCtD
Levomilnacipran—Urinary tract disorder—Doxorubicin—ovarian cancer	0.000212	0.00112	CcSEcCtD
Levomilnacipran—Oedema peripheral—Doxorubicin—ovarian cancer	0.000211	0.00112	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.000211	0.00112	CcSEcCtD
Levomilnacipran—Connective tissue disorder—Doxorubicin—ovarian cancer	0.000211	0.00112	CcSEcCtD
Levomilnacipran—Fatigue—Docetaxel—ovarian cancer	0.00021	0.00111	CcSEcCtD
Levomilnacipran—Angiopathy—Epirubicin—ovarian cancer	0.00021	0.00111	CcSEcCtD
Levomilnacipran—Urethral disorder—Doxorubicin—ovarian cancer	0.00021	0.00111	CcSEcCtD
Levomilnacipran—Mediastinal disorder—Epirubicin—ovarian cancer	0.000209	0.00111	CcSEcCtD
Levomilnacipran—Constipation—Docetaxel—ovarian cancer	0.000209	0.00111	CcSEcCtD
Levomilnacipran—Chills—Epirubicin—ovarian cancer	0.000208	0.0011	CcSEcCtD
Levomilnacipran—Asthenia—Paclitaxel—ovarian cancer	0.000207	0.00109	CcSEcCtD
Levomilnacipran—Pruritus—Paclitaxel—ovarian cancer	0.000204	0.00108	CcSEcCtD
Levomilnacipran—Mental disorder—Epirubicin—ovarian cancer	0.000203	0.00107	CcSEcCtD
Levomilnacipran—Erythema multiforme—Doxorubicin—ovarian cancer	0.000203	0.00107	CcSEcCtD
Levomilnacipran—Malnutrition—Epirubicin—ovarian cancer	0.000202	0.00107	CcSEcCtD
Levomilnacipran—Eye disorder—Doxorubicin—ovarian cancer	0.0002	0.00106	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Docetaxel—ovarian cancer	0.0002	0.00106	CcSEcCtD
Levomilnacipran—Flushing—Doxorubicin—ovarian cancer	0.000199	0.00105	CcSEcCtD
Levomilnacipran—Cardiac disorder—Doxorubicin—ovarian cancer	0.000199	0.00105	CcSEcCtD
Levomilnacipran—Flatulence—Epirubicin—ovarian cancer	0.000199	0.00105	CcSEcCtD
Levomilnacipran—Tension—Epirubicin—ovarian cancer	0.000198	0.00105	CcSEcCtD
Levomilnacipran—Dysgeusia—Epirubicin—ovarian cancer	0.000198	0.00105	CcSEcCtD
Levomilnacipran—Diarrhoea—Paclitaxel—ovarian cancer	0.000197	0.00104	CcSEcCtD
Levomilnacipran—ABCB1—myometrium—ovarian cancer	0.000195	0.0234	CbGeAlD
Levomilnacipran—Angiopathy—Doxorubicin—ovarian cancer	0.000195	0.00103	CcSEcCtD
Levomilnacipran—Mediastinal disorder—Doxorubicin—ovarian cancer	0.000193	0.00102	CcSEcCtD
Levomilnacipran—Abdominal pain—Docetaxel—ovarian cancer	0.000193	0.00102	CcSEcCtD
Levomilnacipran—Body temperature increased—Docetaxel—ovarian cancer	0.000193	0.00102	CcSEcCtD
Levomilnacipran—Chills—Doxorubicin—ovarian cancer	0.000192	0.00102	CcSEcCtD
Levomilnacipran—CYP2C8—testis—ovarian cancer	0.000191	0.0229	CbGeAlD
Levomilnacipran—Dizziness—Paclitaxel—ovarian cancer	0.00019	0.00101	CcSEcCtD
Levomilnacipran—Vision blurred—Epirubicin—ovarian cancer	0.00019	0.00101	CcSEcCtD
Levomilnacipran—Mental disorder—Doxorubicin—ovarian cancer	0.000188	0.000994	CcSEcCtD
Levomilnacipran—ABCB1—embryo—ovarian cancer	0.000187	0.0225	CbGeAlD
Levomilnacipran—Malnutrition—Doxorubicin—ovarian cancer	0.000187	0.000988	CcSEcCtD
Levomilnacipran—Agitation—Epirubicin—ovarian cancer	0.000185	0.000981	CcSEcCtD
Levomilnacipran—Flatulence—Doxorubicin—ovarian cancer	0.000184	0.000974	CcSEcCtD
Levomilnacipran—Tension—Doxorubicin—ovarian cancer	0.000183	0.00097	CcSEcCtD
Levomilnacipran—Vomiting—Paclitaxel—ovarian cancer	0.000183	0.000969	CcSEcCtD
Levomilnacipran—Dysgeusia—Doxorubicin—ovarian cancer	0.000183	0.000968	CcSEcCtD
Levomilnacipran—Rash—Paclitaxel—ovarian cancer	0.000182	0.000961	CcSEcCtD
Levomilnacipran—Dermatitis—Paclitaxel—ovarian cancer	0.000181	0.00096	CcSEcCtD
Levomilnacipran—Syncope—Epirubicin—ovarian cancer	0.000181	0.000958	CcSEcCtD
Levomilnacipran—Leukopenia—Epirubicin—ovarian cancer	0.000181	0.000956	CcSEcCtD
Levomilnacipran—Headache—Paclitaxel—ovarian cancer	0.00018	0.000955	CcSEcCtD
Levomilnacipran—Hypersensitivity—Docetaxel—ovarian cancer	0.00018	0.000952	CcSEcCtD
Levomilnacipran—CYP3A4—Liver X Receptor Pathway—FASN—ovarian cancer	0.000178	0.0132	CbGpPWpGaD
Levomilnacipran—Palpitations—Epirubicin—ovarian cancer	0.000178	0.000944	CcSEcCtD
Levomilnacipran—Loss of consciousness—Epirubicin—ovarian cancer	0.000177	0.000939	CcSEcCtD
Levomilnacipran—CYP3A4—Benzo(a)pyrene metabolism—CYP1B1—ovarian cancer	0.000177	0.0131	CbGpPWpGaD
Levomilnacipran—Vision blurred—Doxorubicin—ovarian cancer	0.000176	0.000931	CcSEcCtD
Levomilnacipran—Asthenia—Docetaxel—ovarian cancer	0.000175	0.000927	CcSEcCtD
Levomilnacipran—Convulsion—Epirubicin—ovarian cancer	0.000175	0.000925	CcSEcCtD
Levomilnacipran—Hypertension—Epirubicin—ovarian cancer	0.000174	0.000922	CcSEcCtD
Levomilnacipran—Pruritus—Docetaxel—ovarian cancer	0.000173	0.000914	CcSEcCtD
Levomilnacipran—Chest pain—Epirubicin—ovarian cancer	0.000172	0.000909	CcSEcCtD
Levomilnacipran—Agitation—Doxorubicin—ovarian cancer	0.000172	0.000908	CcSEcCtD
Levomilnacipran—Anxiety—Epirubicin—ovarian cancer	0.000171	0.000906	CcSEcCtD
Levomilnacipran—Nausea—Paclitaxel—ovarian cancer	0.000171	0.000906	CcSEcCtD
Levomilnacipran—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	0.000171	0.000903	CcSEcCtD
Levomilnacipran—SLC6A2—lymph node—ovarian cancer	0.000169	0.0202	CbGeAlD
Levomilnacipran—Dry mouth—Epirubicin—ovarian cancer	0.000168	0.000889	CcSEcCtD
Levomilnacipran—Syncope—Doxorubicin—ovarian cancer	0.000167	0.000886	CcSEcCtD
Levomilnacipran—CYP2C8—Tamoxifen metabolism—CYP1B1—ovarian cancer	0.000167	0.0124	CbGpPWpGaD
Levomilnacipran—Leukopenia—Doxorubicin—ovarian cancer	0.000167	0.000885	CcSEcCtD
Levomilnacipran—Diarrhoea—Docetaxel—ovarian cancer	0.000167	0.000884	CcSEcCtD
Levomilnacipran—Palpitations—Doxorubicin—ovarian cancer	0.000165	0.000873	CcSEcCtD
Levomilnacipran—Loss of consciousness—Doxorubicin—ovarian cancer	0.000164	0.000869	CcSEcCtD
Levomilnacipran—Infection—Epirubicin—ovarian cancer	0.000164	0.000866	CcSEcCtD
Levomilnacipran—Shock—Epirubicin—ovarian cancer	0.000162	0.000858	CcSEcCtD
Levomilnacipran—Convulsion—Doxorubicin—ovarian cancer	0.000162	0.000856	CcSEcCtD
Levomilnacipran—Nervous system disorder—Epirubicin—ovarian cancer	0.000161	0.000855	CcSEcCtD
Levomilnacipran—Dizziness—Docetaxel—ovarian cancer	0.000161	0.000855	CcSEcCtD
Levomilnacipran—Thrombocytopenia—Epirubicin—ovarian cancer	0.000161	0.000853	CcSEcCtD
Levomilnacipran—Hypertension—Doxorubicin—ovarian cancer	0.000161	0.000853	CcSEcCtD
Levomilnacipran—Tachycardia—Epirubicin—ovarian cancer	0.000161	0.000851	CcSEcCtD
Levomilnacipran—CYP3A4—female reproductive system—ovarian cancer	0.00016	0.0193	CbGeAlD
Levomilnacipran—CYP3A4—Codeine and Morphine Metabolism—ABCB1—ovarian cancer	0.00016	0.0119	CbGpPWpGaD
Levomilnacipran—Skin disorder—Epirubicin—ovarian cancer	0.00016	0.000847	CcSEcCtD
Levomilnacipran—Hyperhidrosis—Epirubicin—ovarian cancer	0.000159	0.000843	CcSEcCtD
Levomilnacipran—Chest pain—Doxorubicin—ovarian cancer	0.000159	0.000841	CcSEcCtD
Levomilnacipran—Anxiety—Doxorubicin—ovarian cancer	0.000158	0.000838	CcSEcCtD
Levomilnacipran—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	0.000158	0.000835	CcSEcCtD
Levomilnacipran—CYP2D6—female reproductive system—ovarian cancer	0.000158	0.0189	CbGeAlD
Levomilnacipran—Anorexia—Epirubicin—ovarian cancer	0.000157	0.000831	CcSEcCtD
Levomilnacipran—Dry mouth—Doxorubicin—ovarian cancer	0.000155	0.000823	CcSEcCtD
Levomilnacipran—Vomiting—Docetaxel—ovarian cancer	0.000155	0.000822	CcSEcCtD
Levomilnacipran—Rash—Docetaxel—ovarian cancer	0.000154	0.000815	CcSEcCtD
Levomilnacipran—Hypotension—Epirubicin—ovarian cancer	0.000154	0.000814	CcSEcCtD
Levomilnacipran—Dermatitis—Docetaxel—ovarian cancer	0.000154	0.000814	CcSEcCtD
Levomilnacipran—Headache—Docetaxel—ovarian cancer	0.000153	0.00081	CcSEcCtD
Levomilnacipran—ABCB1—epithelium—ovarian cancer	0.000153	0.0183	CbGeAlD
Levomilnacipran—ABCB1—uterine cervix—ovarian cancer	0.000151	0.0182	CbGeAlD
Levomilnacipran—Infection—Doxorubicin—ovarian cancer	0.000151	0.000801	CcSEcCtD
Levomilnacipran—Shock—Doxorubicin—ovarian cancer	0.00015	0.000793	CcSEcCtD
Levomilnacipran—Nervous system disorder—Doxorubicin—ovarian cancer	0.000149	0.000791	CcSEcCtD
Levomilnacipran—CYP2C19—Tamoxifen metabolism—CYP1B1—ovarian cancer	0.000149	0.0111	CbGpPWpGaD
Levomilnacipran—Thrombocytopenia—Doxorubicin—ovarian cancer	0.000149	0.00079	CcSEcCtD
Levomilnacipran—Insomnia—Epirubicin—ovarian cancer	0.000149	0.000788	CcSEcCtD
Levomilnacipran—Tachycardia—Doxorubicin—ovarian cancer	0.000149	0.000787	CcSEcCtD
Levomilnacipran—Skin disorder—Doxorubicin—ovarian cancer	0.000148	0.000783	CcSEcCtD
Levomilnacipran—Paraesthesia—Epirubicin—ovarian cancer	0.000148	0.000783	CcSEcCtD
Levomilnacipran—Hyperhidrosis—Doxorubicin—ovarian cancer	0.000147	0.00078	CcSEcCtD
Levomilnacipran—Dyspnoea—Epirubicin—ovarian cancer	0.000147	0.000777	CcSEcCtD
Levomilnacipran—Somnolence—Epirubicin—ovarian cancer	0.000146	0.000775	CcSEcCtD
Levomilnacipran—Anorexia—Doxorubicin—ovarian cancer	0.000145	0.000769	CcSEcCtD
Levomilnacipran—SLC6A4—Circadian rythm related genes—TOP1—ovarian cancer	0.000145	0.0108	CbGpPWpGaD
Levomilnacipran—Nausea—Docetaxel—ovarian cancer	0.000145	0.000768	CcSEcCtD
Levomilnacipran—Dyspepsia—Epirubicin—ovarian cancer	0.000145	0.000767	CcSEcCtD
Levomilnacipran—ABCB1—decidua—ovarian cancer	0.000144	0.0173	CbGeAlD
Levomilnacipran—CYP2D6—female gonad—ovarian cancer	0.000144	0.0172	CbGeAlD
Levomilnacipran—Decreased appetite—Epirubicin—ovarian cancer	0.000143	0.000758	CcSEcCtD
Levomilnacipran—Hypotension—Doxorubicin—ovarian cancer	0.000142	0.000754	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.000142	0.000752	CcSEcCtD
Levomilnacipran—Fatigue—Epirubicin—ovarian cancer	0.000142	0.000751	CcSEcCtD
Levomilnacipran—Constipation—Epirubicin—ovarian cancer	0.000141	0.000745	CcSEcCtD
Levomilnacipran—Insomnia—Doxorubicin—ovarian cancer	0.000138	0.000729	CcSEcCtD
Levomilnacipran—CYP2D6—Tamoxifen metabolism—CYP1B1—ovarian cancer	0.000137	0.0102	CbGpPWpGaD
Levomilnacipran—ABCB1—endometrium—ovarian cancer	0.000137	0.0165	CbGeAlD
Levomilnacipran—Paraesthesia—Doxorubicin—ovarian cancer	0.000137	0.000724	CcSEcCtD
Levomilnacipran—Dyspnoea—Doxorubicin—ovarian cancer	0.000136	0.000719	CcSEcCtD
Levomilnacipran—Somnolence—Doxorubicin—ovarian cancer	0.000135	0.000717	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Epirubicin—ovarian cancer	0.000135	0.000713	CcSEcCtD
Levomilnacipran—Dyspepsia—Doxorubicin—ovarian cancer	0.000134	0.00071	CcSEcCtD
Levomilnacipran—Decreased appetite—Doxorubicin—ovarian cancer	0.000132	0.000701	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Doxorubicin—ovarian cancer	0.000132	0.000696	CcSEcCtD
Levomilnacipran—Fatigue—Doxorubicin—ovarian cancer	0.000131	0.000695	CcSEcCtD
Levomilnacipran—Urticaria—Epirubicin—ovarian cancer	0.000131	0.000692	CcSEcCtD
Levomilnacipran—Constipation—Doxorubicin—ovarian cancer	0.00013	0.00069	CcSEcCtD
Levomilnacipran—Abdominal pain—Epirubicin—ovarian cancer	0.00013	0.000689	CcSEcCtD
Levomilnacipran—Body temperature increased—Epirubicin—ovarian cancer	0.00013	0.000689	CcSEcCtD
Levomilnacipran—CYP2D6—testis—ovarian cancer	0.000127	0.0153	CbGeAlD
Levomilnacipran—ABCB1—gonad—ovarian cancer	0.000127	0.0153	CbGeAlD
Levomilnacipran—SLC6A4—Circadian rythm related genes—PPP1CC—ovarian cancer	0.000127	0.00941	CbGpPWpGaD
Levomilnacipran—ABCB1—uterus—ovarian cancer	0.000126	0.0152	CbGeAlD
Levomilnacipran—CYP2J2—Biological oxidations—CYP1B1—ovarian cancer	0.000125	0.00924	CbGpPWpGaD
Levomilnacipran—Gastrointestinal pain—Doxorubicin—ovarian cancer	0.000125	0.000659	CcSEcCtD
Levomilnacipran—CYP2J2—Metapathway biotransformation—CYP1B1—ovarian cancer	0.000123	0.00911	CbGpPWpGaD
Levomilnacipran—Hypersensitivity—Epirubicin—ovarian cancer	0.000121	0.000642	CcSEcCtD
Levomilnacipran—Urticaria—Doxorubicin—ovarian cancer	0.000121	0.000641	CcSEcCtD
Levomilnacipran—Body temperature increased—Doxorubicin—ovarian cancer	0.00012	0.000638	CcSEcCtD
Levomilnacipran—Abdominal pain—Doxorubicin—ovarian cancer	0.00012	0.000638	CcSEcCtD
Levomilnacipran—Asthenia—Epirubicin—ovarian cancer	0.000118	0.000625	CcSEcCtD
Levomilnacipran—Pruritus—Epirubicin—ovarian cancer	0.000116	0.000617	CcSEcCtD
Levomilnacipran—CYP2C19—Melatonin metabolism and effects—CYP1B1—ovarian cancer	0.000115	0.00855	CbGpPWpGaD
Levomilnacipran—ABCB1—female reproductive system—ovarian cancer	0.000114	0.0136	CbGeAlD
Levomilnacipran—Diarrhoea—Epirubicin—ovarian cancer	0.000113	0.000596	CcSEcCtD
Levomilnacipran—Hypersensitivity—Doxorubicin—ovarian cancer	0.000112	0.000594	CcSEcCtD
Levomilnacipran—SLC6A4—Circadian rythm related genes—HNF1B—ovarian cancer	0.00011	0.00815	CbGpPWpGaD
Levomilnacipran—Asthenia—Doxorubicin—ovarian cancer	0.000109	0.000579	CcSEcCtD
Levomilnacipran—Dizziness—Epirubicin—ovarian cancer	0.000109	0.000576	CcSEcCtD
Levomilnacipran—Pruritus—Doxorubicin—ovarian cancer	0.000108	0.000571	CcSEcCtD
Levomilnacipran—ABCB1—bone marrow—ovarian cancer	0.000107	0.0129	CbGeAlD
Levomilnacipran—CYP2D6—Melatonin metabolism and effects—CYP1B1—ovarian cancer	0.000106	0.00787	CbGpPWpGaD
Levomilnacipran—Vomiting—Epirubicin—ovarian cancer	0.000105	0.000554	CcSEcCtD
Levomilnacipran—Diarrhoea—Doxorubicin—ovarian cancer	0.000104	0.000552	CcSEcCtD
Levomilnacipran—Rash—Epirubicin—ovarian cancer	0.000104	0.00055	CcSEcCtD
Levomilnacipran—Dermatitis—Epirubicin—ovarian cancer	0.000104	0.000549	CcSEcCtD
Levomilnacipran—ABCB1—female gonad—ovarian cancer	0.000103	0.0124	CbGeAlD
Levomilnacipran—Headache—Epirubicin—ovarian cancer	0.000103	0.000546	CcSEcCtD
Levomilnacipran—ABCB1—vagina—ovarian cancer	0.000103	0.0123	CbGeAlD
Levomilnacipran—CYP3A4—Estrogen metabolism—CYP1B1—ovarian cancer	0.000102	0.00753	CbGpPWpGaD
Levomilnacipran—Dizziness—Doxorubicin—ovarian cancer	0.000101	0.000533	CcSEcCtD
Levomilnacipran—Nausea—Epirubicin—ovarian cancer	9.78e-05	0.000518	CcSEcCtD
Levomilnacipran—Vomiting—Doxorubicin—ovarian cancer	9.68e-05	0.000513	CcSEcCtD
Levomilnacipran—CYP2J2—Metabolism of lipids and lipoproteins—PPP1CC—ovarian cancer	9.61e-05	0.00712	CbGpPWpGaD
Levomilnacipran—Rash—Doxorubicin—ovarian cancer	9.6e-05	0.000508	CcSEcCtD
Levomilnacipran—Dermatitis—Doxorubicin—ovarian cancer	9.6e-05	0.000508	CcSEcCtD
Levomilnacipran—Headache—Doxorubicin—ovarian cancer	9.54e-05	0.000505	CcSEcCtD
Levomilnacipran—ABCB1—testis—ovarian cancer	9.16e-05	0.011	CbGeAlD
Levomilnacipran—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—SKP2—ovarian cancer	9.08e-05	0.00673	CbGpPWpGaD
Levomilnacipran—Nausea—Doxorubicin—ovarian cancer	9.05e-05	0.000479	CcSEcCtD
Levomilnacipran—CYP3A4—Tamoxifen metabolism—CYP1B1—ovarian cancer	8.98e-05	0.00666	CbGpPWpGaD
Levomilnacipran—SLC6A4—NRF2 pathway—SLC5A5—ovarian cancer	8.81e-05	0.00653	CbGpPWpGaD
Levomilnacipran—CYP2C19—Constitutive Androstane Receptor Pathway—ABCB1—ovarian cancer	8.78e-05	0.00651	CbGpPWpGaD
Levomilnacipran—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—ovarian cancer	8.76e-05	0.00649	CbGpPWpGaD
Levomilnacipran—SLC6A4—NRF2 pathway—SLC2A1—ovarian cancer	8.51e-05	0.00631	CbGpPWpGaD
Levomilnacipran—CYP2C8—Arachidonic acid metabolism—CYP1B1—ovarian cancer	8.36e-05	0.0062	CbGpPWpGaD
Levomilnacipran—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—GADD45A—ovarian cancer	8.12e-05	0.00602	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—NME2—ovarian cancer	7.6e-05	0.00563	CbGpPWpGaD
Levomilnacipran—SLC6A2—NRF2 pathway—SLC5A5—ovarian cancer	7.58e-05	0.00562	CbGpPWpGaD
Levomilnacipran—CYP2C19—Arachidonic acid metabolism—CYP1B1—ovarian cancer	7.46e-05	0.00553	CbGpPWpGaD
Levomilnacipran—CYP3A4—Irinotecan Pathway—APC—ovarian cancer	7.37e-05	0.00547	CbGpPWpGaD
Levomilnacipran—SLC6A2—NRF2 pathway—SLC2A1—ovarian cancer	7.32e-05	0.00543	CbGpPWpGaD
Levomilnacipran—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP1B1—ovarian cancer	7.22e-05	0.00536	CbGpPWpGaD
Levomilnacipran—CYP2C8—Oxidation by Cytochrome P450—CYP1B1—ovarian cancer	7.13e-05	0.00528	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—CD82—ovarian cancer	7.02e-05	0.00521	CbGpPWpGaD
Levomilnacipran—ABCB1—lymph node—ovarian cancer	6.64e-05	0.00797	CbGeAlD
Levomilnacipran—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP1B1—ovarian cancer	6.45e-05	0.00478	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	6.44e-05	0.00478	CbGpPWpGaD
Levomilnacipran—CYP2C19—Oxidation by Cytochrome P450—CYP1B1—ovarian cancer	6.36e-05	0.00472	CbGpPWpGaD
Levomilnacipran—ABCB1—HIF-1-alpha transcription factor network—SLC2A1—ovarian cancer	6.08e-05	0.00451	CbGpPWpGaD
Levomilnacipran—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP1B1—ovarian cancer	5.93e-05	0.0044	CbGpPWpGaD
Levomilnacipran—CYP2C8—Phase 1 - Functionalization of compounds—CYP1B1—ovarian cancer	5.86e-05	0.00434	CbGpPWpGaD
Levomilnacipran—CYP2D6—Oxidation by Cytochrome P450—CYP1B1—ovarian cancer	5.85e-05	0.00434	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—TOP1—ovarian cancer	5.73e-05	0.00424	CbGpPWpGaD
Levomilnacipran—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—ovarian cancer	5.28e-05	0.00391	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	5.25e-05	0.00389	CbGpPWpGaD
Levomilnacipran—CYP2C19—Phase 1 - Functionalization of compounds—CYP1B1—ovarian cancer	5.23e-05	0.00387	CbGpPWpGaD
Levomilnacipran—SLC6A4—Circadian rythm related genes—TYMS—ovarian cancer	5.11e-05	0.00379	CbGpPWpGaD
Levomilnacipran—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—ovarian cancer	5.03e-05	0.00373	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—CYTB—ovarian cancer	4.9e-05	0.00363	CbGpPWpGaD
Levomilnacipran—CYP2D6—Phase 1 - Functionalization of compounds—CYP1B1—ovarian cancer	4.81e-05	0.00356	CbGpPWpGaD
Levomilnacipran—SLC6A2—Transmembrane transport of small molecules—AQP3—ovarian cancer	4.8e-05	0.00356	CbGpPWpGaD
Levomilnacipran—CYP3A4—Tryptophan metabolism—CYP1B1—ovarian cancer	4.8e-05	0.00356	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	4.78e-05	0.00355	CbGpPWpGaD
Levomilnacipran—SLC6A2—SLC-mediated transmembrane transport—SLC5A5—ovarian cancer	4.78e-05	0.00354	CbGpPWpGaD
Levomilnacipran—SLC6A2—SLC-mediated transmembrane transport—SLC2A1—ovarian cancer	4.61e-05	0.00342	CbGpPWpGaD
Levomilnacipran—SLC6A2—Transmembrane transport of small molecules—ATP7B—ovarian cancer	4.6e-05	0.00341	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—PPP1CC—ovarian cancer	4.28e-05	0.00317	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—BRIP1—ovarian cancer	4.28e-05	0.00317	CbGpPWpGaD
Levomilnacipran—ABCB1—HIF-1-alpha transcription factor network—TERT—ovarian cancer	4.11e-05	0.00305	CbGpPWpGaD
Levomilnacipran—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1B1—ovarian cancer	3.88e-05	0.00287	CbGpPWpGaD
Levomilnacipran—CYP3A4—Oxidation by Cytochrome P450—CYP1B1—ovarian cancer	3.83e-05	0.00284	CbGpPWpGaD
Levomilnacipran—SLC6A2—Transmembrane transport of small molecules—TUBB3—ovarian cancer	3.64e-05	0.0027	CbGpPWpGaD
Levomilnacipran—SLC6A4—SIDS Susceptibility Pathways—CXCL8—ovarian cancer	3.38e-05	0.00251	CbGpPWpGaD
Levomilnacipran—SLC6A4—SIDS Susceptibility Pathways—CASP3—ovarian cancer	3.24e-05	0.0024	CbGpPWpGaD
Levomilnacipran—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—CDKN1B—ovarian cancer	3.16e-05	0.00234	CbGpPWpGaD
Levomilnacipran—CYP3A4—Phase 1 - Functionalization of compounds—CYP1B1—ovarian cancer	3.14e-05	0.00233	CbGpPWpGaD
Levomilnacipran—SLC6A4—SIDS Susceptibility Pathways—CTNNB1—ovarian cancer	3.12e-05	0.00231	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	3.12e-05	0.00231	CbGpPWpGaD
Levomilnacipran—CYP2C8—Biological oxidations—CYP1B1—ovarian cancer	3.11e-05	0.00231	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metapathway biotransformation—CYP1B1—ovarian cancer	3.07e-05	0.00227	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—YAP1—ovarian cancer	2.87e-05	0.00213	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	2.84e-05	0.00211	CbGpPWpGaD
Levomilnacipran—CYP2C19—Biological oxidations—CYP1B1—ovarian cancer	2.78e-05	0.00206	CbGpPWpGaD
Levomilnacipran—SLC6A4—SIDS Susceptibility Pathways—VEGFA—ovarian cancer	2.75e-05	0.00204	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metapathway biotransformation—CYP1B1—ovarian cancer	2.74e-05	0.00203	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—GADD45A—ovarian cancer	2.74e-05	0.00203	CbGpPWpGaD
Levomilnacipran—CYP2D6—Biological oxidations—CYP1B1—ovarian cancer	2.55e-05	0.00189	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metapathway biotransformation—CYP1B1—ovarian cancer	2.52e-05	0.00187	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—ovarian cancer	2.5e-05	0.00185	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	2.5e-05	0.00185	CbGpPWpGaD
Levomilnacipran—SLC6A4—Circadian rythm related genes—PTEN—ovarian cancer	2.48e-05	0.00184	CbGpPWpGaD
Levomilnacipran—SLC6A2—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	2.43e-05	0.0018	CbGpPWpGaD
Levomilnacipran—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—ovarian cancer	2.42e-05	0.00179	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—PPP1CC—ovarian cancer	2.4e-05	0.00178	CbGpPWpGaD
Levomilnacipran—SLC6A2—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	2.34e-05	0.00174	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA1—ovarian cancer	2.34e-05	0.00174	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—FASN—ovarian cancer	2.34e-05	0.00173	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—SLC5A5—ovarian cancer	2.3e-05	0.00171	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—SLC2A1—ovarian cancer	2.22e-05	0.00165	CbGpPWpGaD
Levomilnacipran—ABCB1—Allograft Rejection—CXCL8—ovarian cancer	2.21e-05	0.00164	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	2.18e-05	0.00161	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—PPP1CC—ovarian cancer	2.14e-05	0.00159	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—CYP1B1—ovarian cancer	2.13e-05	0.00158	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—ovarian cancer	2.12e-05	0.00157	CbGpPWpGaD
Levomilnacipran—ABCB1—Transmembrane transport of small molecules—AQP3—ovarian cancer	2.11e-05	0.00157	CbGpPWpGaD
Levomilnacipran—ABCB1—Allograft Rejection—CASP3—ovarian cancer	2.11e-05	0.00157	CbGpPWpGaD
Levomilnacipran—ABCB1—Allograft Rejection—IL2—ovarian cancer	2.11e-05	0.00156	CbGpPWpGaD
Levomilnacipran—ABCB1—HIF-1-alpha transcription factor network—VEGFA—ovarian cancer	2.07e-05	0.00153	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—CCNE1—ovarian cancer	2.05e-05	0.00152	CbGpPWpGaD
Levomilnacipran—ABCB1—Transmembrane transport of small molecules—ATP7B—ovarian cancer	2.03e-05	0.0015	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—TYMS—ovarian cancer	2.02e-05	0.00149	CbGpPWpGaD
Levomilnacipran—SLC6A4—SIDS Susceptibility Pathways—IL6—ovarian cancer	1.9e-05	0.00141	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—NME2—ovarian cancer	1.9e-05	0.00141	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—PPP2R1A—ovarian cancer	1.89e-05	0.0014	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	1.88e-05	0.00139	CbGpPWpGaD
Levomilnacipran—SLC6A2—Transmembrane transport of small molecules—ABCB1—ovarian cancer	1.85e-05	0.00137	CbGpPWpGaD
Levomilnacipran—ABCB1—Allograft Rejection—VEGFA—ovarian cancer	1.79e-05	0.00133	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—ABCB1—ovarian cancer	1.75e-05	0.0013	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—TYMS—ovarian cancer	1.72e-05	0.00128	CbGpPWpGaD
Levomilnacipran—SLC6A4—Circadian rythm related genes—TP53—ovarian cancer	1.69e-05	0.00126	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—NME2—ovarian cancer	1.69e-05	0.00125	CbGpPWpGaD
Levomilnacipran—CYP3A4—Biological oxidations—CYP1B1—ovarian cancer	1.67e-05	0.00124	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—NME2—ovarian cancer	1.65e-05	0.00122	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metapathway biotransformation—CYP1B1—ovarian cancer	1.65e-05	0.00122	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	1.61e-05	0.00119	CbGpPWpGaD
Levomilnacipran—ABCB1—Transmembrane transport of small molecules—TUBB3—ovarian cancer	1.6e-05	0.00119	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—ovarian cancer	1.56e-05	0.00116	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—NME2—ovarian cancer	1.56e-05	0.00115	CbGpPWpGaD
Levomilnacipran—SLC6A4—Circadian rythm related genes—IL6—ovarian cancer	1.55e-05	0.00115	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—APC—ovarian cancer	1.48e-05	0.0011	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	1.44e-05	0.00106	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—CAV1—ovarian cancer	1.39e-05	0.00103	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.33e-05	0.000984	CbGpPWpGaD
Levomilnacipran—ABCB1—HIF-1-alpha transcription factor network—AKT1—ovarian cancer	1.32e-05	0.000979	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	1.31e-05	0.000972	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—PIK3CG—ovarian cancer	1.26e-05	0.000938	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—CYTB—ovarian cancer	1.22e-05	0.000906	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	1.19e-05	0.000886	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	1.17e-05	0.000868	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—ovarian cancer	1.15e-05	0.000852	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—PIK3CD—ovarian cancer	1.11e-05	0.000824	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—CYTB—ovarian cancer	1.09e-05	0.000809	CbGpPWpGaD
Levomilnacipran—ABCB1—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	1.07e-05	0.000792	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—PPP1CC—ovarian cancer	1.07e-05	0.000792	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—BRIP1—ovarian cancer	1.07e-05	0.000792	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	1.07e-05	0.00079	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—CYTB—ovarian cancer	1.06e-05	0.000789	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—ovarian cancer	1.06e-05	0.000789	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—ovarian cancer	1.04e-05	0.000773	CbGpPWpGaD
Levomilnacipran—ABCB1—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	1.03e-05	0.000765	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—NME2—ovarian cancer	1.02e-05	0.000755	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—ovarian cancer	1.01e-05	0.000752	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—ovarian cancer	1e-05	0.000745	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—CYTB—ovarian cancer	1e-05	0.000744	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—ovarian cancer	9.8e-06	0.000726	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—PIK3CB—ovarian cancer	9.69e-06	0.000719	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—PPP1CC—ovarian cancer	9.54e-06	0.000707	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—BRIP1—ovarian cancer	9.54e-06	0.000707	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—PPP1CC—ovarian cancer	9.31e-06	0.00069	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—BRIP1—ovarian cancer	9.31e-06	0.00069	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—ovarian cancer	8.85e-06	0.000656	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—PPP1CC—ovarian cancer	8.77e-06	0.00065	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—BRIP1—ovarian cancer	8.77e-06	0.00065	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—PTEN—ovarian cancer	8.38e-06	0.000621	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—ovarian cancer	8.37e-06	0.00062	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—ovarian cancer	8.14e-06	0.000603	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—ovarian cancer	7.96e-06	0.00059	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—ovarian cancer	7.96e-06	0.00059	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	7.78e-06	0.000577	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—ovarian cancer	7.52e-06	0.000558	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—YAP1—ovarian cancer	7.16e-06	0.000531	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	7.09e-06	0.000526	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	6.95e-06	0.000515	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—ovarian cancer	6.91e-06	0.000512	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—ovarian cancer	6.68e-06	0.000496	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—CYTB—ovarian cancer	6.56e-06	0.000486	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—YAP1—ovarian cancer	6.4e-06	0.000474	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	6.33e-06	0.000469	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—YAP1—ovarian cancer	6.24e-06	0.000463	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	6.23e-06	0.000462	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—PIK3CA—ovarian cancer	5.91e-06	0.000438	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—YAP1—ovarian cancer	5.88e-06	0.000436	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—FASN—ovarian cancer	5.84e-06	0.000433	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—SLC5A5—ovarian cancer	5.75e-06	0.000426	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—BRIP1—ovarian cancer	5.73e-06	0.000425	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PPP1CC—ovarian cancer	5.73e-06	0.000425	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	5.65e-06	0.000418	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	5.56e-06	0.000412	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—SLC2A1—ovarian cancer	5.55e-06	0.000411	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	5.43e-06	0.000403	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—CYP1B1—ovarian cancer	5.32e-06	0.000394	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—FASN—ovarian cancer	5.21e-06	0.000386	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—SLC5A5—ovarian cancer	5.13e-06	0.00038	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—FASN—ovarian cancer	5.09e-06	0.000377	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—SLC5A5—ovarian cancer	5.01e-06	0.000371	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—SLC2A1—ovarian cancer	4.95e-06	0.000367	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	4.85e-06	0.00036	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—SLC2A1—ovarian cancer	4.83e-06	0.000358	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—AKT1—ovarian cancer	4.83e-06	0.000358	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—FASN—ovarian cancer	4.8e-06	0.000355	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—CYP1B1—ovarian cancer	4.75e-06	0.000352	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—PPP2R1A—ovarian cancer	4.72e-06	0.00035	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—SLC5A5—ovarian cancer	4.72e-06	0.00035	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	4.69e-06	0.000348	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—CYP1B1—ovarian cancer	4.63e-06	0.000344	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—SLC2A1—ovarian cancer	4.56e-06	0.000338	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—ABCB1—ovarian cancer	4.38e-06	0.000325	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—CYP1B1—ovarian cancer	4.37e-06	0.000324	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—TYMS—ovarian cancer	4.3e-06	0.000319	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—PPP2R1A—ovarian cancer	4.21e-06	0.000312	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	4.19e-06	0.000311	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—PPP2R1A—ovarian cancer	4.11e-06	0.000305	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—ABCB1—ovarian cancer	3.91e-06	0.00029	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—PPP2R1A—ovarian cancer	3.87e-06	0.000287	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—YAP1—ovarian cancer	3.85e-06	0.000285	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—TYMS—ovarian cancer	3.84e-06	0.000285	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—TYMS—ovarian cancer	3.75e-06	0.000278	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—ABCB1—ovarian cancer	3.6e-06	0.000267	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—TYMS—ovarian cancer	3.53e-06	0.000262	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—CAV1—ovarian cancer	3.47e-06	0.000257	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	3.31e-06	0.000246	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—PIK3CG—ovarian cancer	3.16e-06	0.000234	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—FASN—ovarian cancer	3.14e-06	0.000232	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—CAV1—ovarian cancer	3.09e-06	0.000229	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—SLC5A5—ovarian cancer	3.08e-06	0.000229	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—CAV1—ovarian cancer	3.02e-06	0.000224	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—SLC2A1—ovarian cancer	2.98e-06	0.000221	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	2.96e-06	0.000219	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—CYP1B1—ovarian cancer	2.86e-06	0.000212	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—CAV1—ovarian cancer	2.85e-06	0.000211	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—PIK3CG—ovarian cancer	2.82e-06	0.000209	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—PIK3CD—ovarian cancer	2.78e-06	0.000206	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—PIK3CG—ovarian cancer	2.75e-06	0.000204	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—PIK3CG—ovarian cancer	2.59e-06	0.000192	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	2.53e-06	0.000188	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—PIK3CD—ovarian cancer	2.48e-06	0.000184	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—PIK3CB—ovarian cancer	2.42e-06	0.000179	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—PIK3CD—ovarian cancer	2.42e-06	0.000179	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—ABCB1—ovarian cancer	2.35e-06	0.000174	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—TYMS—ovarian cancer	2.31e-06	0.000171	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—PIK3CD—ovarian cancer	2.28e-06	0.000169	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—PIK3CB—ovarian cancer	2.16e-06	0.00016	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—PIK3CB—ovarian cancer	2.11e-06	0.000156	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—PTEN—ovarian cancer	2.09e-06	0.000155	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—PIK3CB—ovarian cancer	1.99e-06	0.000147	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—PTEN—ovarian cancer	1.87e-06	0.000138	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—CAV1—ovarian cancer	1.86e-06	0.000138	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—PTEN—ovarian cancer	1.82e-06	0.000135	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—PTEN—ovarian cancer	1.72e-06	0.000127	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PIK3CG—ovarian cancer	1.69e-06	0.000126	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PIK3CD—ovarian cancer	1.49e-06	0.00011	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—PIK3CA—ovarian cancer	1.48e-06	0.000109	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—PIK3CA—ovarian cancer	1.32e-06	9.76e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PIK3CB—ovarian cancer	1.3e-06	9.63e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—PIK3CA—ovarian cancer	1.29e-06	9.53e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—PIK3CA—ovarian cancer	1.21e-06	8.98e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—AKT1—ovarian cancer	1.2e-06	8.93e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PTEN—ovarian cancer	1.12e-06	8.32e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—AKT1—ovarian cancer	1.08e-06	7.97e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—AKT1—ovarian cancer	1.05e-06	7.78e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—AKT1—ovarian cancer	9.89e-07	7.33e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PIK3CA—ovarian cancer	7.92e-07	5.87e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—AKT1—ovarian cancer	6.47e-07	4.79e-05	CbGpPWpGaD
